Study: Saxagliptin Offers Renal Protection


A rat study shows saxagliptin has promise for renal protection.

Rats fed a high-salt diet and treated with saxagliptin (Onglyza/AstraZeneca) a potent inhibitor of the DPP-4 enzyme, showed markedly ameliorated urinary albumin excretions, a Japanese team found. The research is due to be reported in an abstract at a poster session June 6 at the American Diabetes Association meeting in Boston, MA.

The study animals also had fewer renal glomerular and tubular injuries, researchers Masako Uchii and colleagues at the Pharmaceutical Researcher Center, Kyowa Hakko Kirin Co., in Shizuoka, Japan wrote. The drug did not lower their blood pressure or blood glucose levels. Saxagliptin also strongly inhibited in situ glomerular and tubular DPP-4 activities.

In addition, saxagliptin significantly attenuated up-regulation of renal mRNA expressions of IL-6, Pal-1, Collagen I, and Collagen II.

“Our results demonstrated that saxagliptin inhibited the development of renal injury independent of its glucose-lowering effect and that the glomerular and tubular DPP-4 inhibitions by saxagliptin were associated with amelioration of kidney injury,” in the rats. That holds promise for renal protection, the team concluded.

Recent Videos
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
Brendon Neuen, MBBS, PhD | Credit:
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Signs and Symptoms of Connective Tissue Disease
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
© 2024 MJH Life Sciences

All rights reserved.